Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials
Toshiyuki Harada(Hokkaido hospital), Masaharu Nishimura(Hokkaido Institute of Public Health), Hiroshi Isobe, Takahiro Ogi(Obihiro Kosei General Hospital), Noriyuki Yamada(Miwa Hospital), Hirotoshi Dosaka‐Akita(Hokkaido University Hospital), Hiroshi Yokouchi(National Hospital Organization Hokkaido Medical Center), Kei Takamura(Obihiro Kosei General Hospital), Shunsuke Okumura(Asahikawa Medical University), Tomoo Ikari(Hokkaido hospital), Kageaki Taima(Hirosaki University), Toraji Amano(Hokkaido University Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Toshiaki Fujikane(Asahikawa Medical University), Yuka Fujita, Hisashi Tanaka(Hirosaki University), Takaaki Sasaki(Asahikawa Medical College Hospital), Naoto Morikawa(Tohoku University)
Cited by 19
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
|Nature Immunology|2012|832
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695